"Dopamine Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.
| Descriptor ID |
D015259
|
| MeSH Number(s) |
D27.505.519.625.150 D27.505.696.577.150
|
| Concept/Terms |
Dopamine Agents- Dopamine Agents
- Agents, Dopamine
- Dopaminergic Agents
- Agents, Dopaminergic
- Dopaminergic Drugs
- Drugs, Dopaminergic
- Dopamine Drugs
- Drugs, Dopamine
Dopamine Effect- Dopamine Effect
- Effect, Dopamine
- Dopaminergic Effect
- Effect, Dopaminergic
- Dopaminergic Effects
- Effects, Dopaminergic
- Dopamine Effects
- Effects, Dopamine
|
Below are MeSH descriptors whose meaning is more general than "Dopamine Agents".
Below are MeSH descriptors whose meaning is more specific than "Dopamine Agents".
This graph shows the total number of publications written about "Dopamine Agents" by people in this website by year, and whether "Dopamine Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1997 | 1 | 0 | 1 |
| 1998 | 3 | 0 | 3 |
| 1999 | 1 | 3 | 4 |
| 2000 | 1 | 1 | 2 |
| 2002 | 1 | 1 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dopamine Agents" by people in Profiles.
-
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. Neurology. 2021 11 16; 97(20):942-957.
-
Experimental colitis promotes sustained, sex-dependent, T-cell-associated neuroinflammation and parkinsonian neuropathology. Acta Neuropathol Commun. 2021 08 19; 9(1):139.
-
The gut microbiome in Parkinson's disease: A culprit or a bystander? Prog Brain Res. 2020; 252:357-450.
-
Motor phenotype classification in moderate to advanced PD in BioFIND study. Parkinsonism Relat Disord. 2019 08; 65:178-183.
-
A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Mov Disord. 2016 09; 31(9):1373-80.
-
Pridopidine for the treatment of Huntington's disease. Expert Opin Investig Drugs. 2016; 25(4):485-92.
-
Therapeutic advances in restless legs syndrome (RLS). Mov Disord. 2015 Sep 15; 30(11):1574-9.
-
Treatment of restless legs syndrome. Neurotherapeutics. 2014 Jan; 11(1):177-87.
-
Vitamin E, memantine, and Alzheimer disease. JAMA. 2014 Jan 01; 311(1):29-30.
-
Wearing-off scales in Parkinson's disease: critique and recommendations. Mov Disord. 2011 Oct; 26(12):2169-75.